E Giovannetti1, P A Zucali2, Y G Assaraf3, N Funel4, M Gemelli2, M Stark3, E Thunnissen5, Z Hou6, I B Muller7, E A Struys7, M Perrino2, G Jansen8, L H Matherly6, G J Peters9. 1. Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands; Cancer Pharmacology Lab, AIRC Start-Up Unit, Department of Translational Research and The New Technologies in Medicine and Surgery, University of Pisa, Pisa. 2. Department of Oncology, University of Milan, Humanitas Clinical and Research Hospital, Rozzano (Milan), Italy. 3. Department of Biology, Fred Wyszkowski Cancer Research Laboratory, Technion-Institute of Technology, Haifa, Israel. 4. Cancer Pharmacology Lab, AIRC Start-Up Unit, Department of Translational Research and The New Technologies in Medicine and Surgery, University of Pisa, Pisa. 5. Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. 6. Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA. 7. Department of Clinical Chemistry, VU University Medical Center, Amsterdam. 8. Amsterdam Rheumatology and Immunology Center - Location VUmc, Amsterdam, The Netherlands. 9. Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands. Electronic address: gj.peters@vumc.nl.
Abstract
BACKGROUND: Thymidylate synthase (TS) has a predictive role in pemetrexed treatment of mesothelioma; however, additional chemoresistance mechanisms are poorly understood. Here, we explored the role of the reduced-folate carrier (RFC/SLC19A1) and proton-coupled folate transporter (PCFT/SLC46A1) in antifolate resistance in mesothelioma. PATIENTS AND METHODS: PCFT, RFC and TS RNA and PCFT protein levels were determined by quantitative RT-PCR of frozen tissues and immunohistochemistry of tissue-microarrays, respectively, in two cohorts of pemetrexed-treated patients. Data were analyzed by t-test, Fisher's/log-rank test and Cox proportional models. The contribution of PCFT expression and PCFT-promoter methylation to pemetrexed activity were evaluated in mesothelioma cells and spheroids, through 5-aza-2'-deoxycytidine-mediated demethylation and siRNA-knockdown. RESULTS: Pemetrexed-treated patients with low PCFT had significantly lower rates of disease control, and shorter overall survival (OS), in both the test (N = 73, 11.3 versus 20.1 months, P = 0.01) and validation (N = 51, 12.6 versus 30.3 months, P = 0.02) cohorts. Multivariate analysis confirmed PCFT-independent prognostic role. Low-PCFT protein levels were also associated with shorter OS. Patients with both low-PCFT and high-TS levels had the worst prognosis (OS, 5.5 months), whereas associations were neither found for RFC nor in pemetrexed-untreated patients. PCFT silencing reduced pemetrexed sensitivity, whereas 5-aza-2'-deoxycytidine overcame resistance. CONCLUSIONS: These findings identify for the first time PCFT as a novel mesothelioma prognostic biomarker, prompting prospective trials for its validation. Moreover, preclinical data suggest that targeting PCFT-promoter methylation might eradicate pemetrexed-resistant cells characterized by low-PCFT expression.
BACKGROUND: Thymidylate synthase (TS) has a predictive role in pemetrexed treatment of mesothelioma; however, additional chemoresistance mechanisms are poorly understood. Here, we explored the role of the reduced-folate carrier (RFC/SLC19A1) and proton-coupled folate transporter (PCFT/SLC46A1) in antifolate resistance in mesothelioma. PATIENTS AND METHODS: PCFT, RFC and TS RNA and PCFT protein levels were determined by quantitative RT-PCR of frozen tissues and immunohistochemistry of tissue-microarrays, respectively, in two cohorts of pemetrexed-treated patients. Data were analyzed by t-test, Fisher's/log-rank test and Cox proportional models. The contribution of PCFT expression and PCFT-promoter methylation to pemetrexed activity were evaluated in mesothelioma cells and spheroids, through 5-aza-2'-deoxycytidine-mediated demethylation and siRNA-knockdown. RESULTS: Pemetrexed-treated patients with low PCFT had significantly lower rates of disease control, and shorter overall survival (OS), in both the test (N = 73, 11.3 versus 20.1 months, P = 0.01) and validation (N = 51, 12.6 versus 30.3 months, P = 0.02) cohorts. Multivariate analysis confirmed PCFT-independent prognostic role. Low-PCFT protein levels were also associated with shorter OS. Patients with both low-PCFT and high-TS levels had the worst prognosis (OS, 5.5 months), whereas associations were neither found for RFC nor in pemetrexed-untreated patients. PCFT silencing reduced pemetrexed sensitivity, whereas 5-aza-2'-deoxycytidine overcame resistance. CONCLUSIONS: These findings identify for the first time PCFT as a novel mesothelioma prognostic biomarker, prompting prospective trials for its validation. Moreover, preclinical data suggest that targeting PCFT-promoter methylation might eradicate pemetrexed-resistant cells characterized by low-PCFT expression.
Authors: Paolo Andrea Zucali; Elisa Giovannetti; Annarita Destro; Manlio Mencoboni; Giovanni Luca Ceresoli; Letizia Gianoncelli; Elena Lorenzi; Fabio De Vincenzo; Matteo Simonelli; Matteo Perrino; Andrea Bruzzone; Erik Thunnissen; Gianni Tunesi; Laura Giordano; Massimo Roncalli; Godefridus J Peters; Armando Santoro Journal: Clin Cancer Res Date: 2011-01-24 Impact factor: 12.531
Authors: Giovanni L Ceresoli; Paolo A Zucali; Adolfo G Favaretto; Francesco Grossi; Paolo Bidoli; Guido Del Conte; Anna Ceribelli; Alessandra Bearz; Emanuela Morenghi; Raffaele Cavina; Maurizio Marangolo; Hector J Soto Parra; Armando Santoro Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: E Giovannetti; P A Zucali; Y G Assaraf; L G Leon; K Smid; C Alecci; F Giancola; A Destro; L Gianoncelli; E Lorenzi; M Roncalli; A Santoro; G J Peters Journal: Br J Cancer Date: 2011-10-04 Impact factor: 7.640
Authors: J E Nutt; A R A Razak; K O'Toole; F Black; A E Quinn; A H Calvert; E R Plummer; J Lunec Journal: Br J Cancer Date: 2010-01-05 Impact factor: 7.640
Authors: Michele Carbone; Shreya Kanodia; Ann Chao; Aubrey Miller; Anil Wali; David Weissman; Alex Adjei; Francine Baumann; Paolo Boffetta; Brenda Buck; Marc de Perrot; A Umran Dogan; Steve Gavett; Alessandro Gualtieri; Raffit Hassan; Mary Hesdorffer; Fred R Hirsch; David Larson; Weimin Mao; Scott Masten; Harvey I Pass; Julian Peto; Enrico Pira; Ian Steele; Anne Tsao; Gavitt Alida Woodard; Haining Yang; Shakun Malik Journal: J Thorac Oncol Date: 2016-08 Impact factor: 15.609
Authors: Manasa Ravindra; Adrianne Wallace-Povirk; Mohammad A Karim; Mike R Wilson; Carrie O'Connor; Kathryn White; Juiwanna Kushner; Lisa Polin; Christina George; Zhanjun Hou; Larry H Matherly; Aleem Gangjee Journal: J Med Chem Date: 2018-02-21 Impact factor: 7.446
Authors: Joanne L Parker; Justin C Deme; Gabriel Kuteyi; Zhiyi Wu; Jiandong Huo; I David Goldman; Raymond J Owens; Philip C Biggin; Susan M Lea; Simon Newstead Journal: Nature Date: 2021-05-26 Impact factor: 49.962